Toxicokinetics & Dosing Limits
• Static ataxia & marked lethargy
• Urinary incontinence (~50% pathognomonic)
• Hyperesthesia & startle response
• Hypothermia & bradycardia / tachycardia
• Oral MLD: >3 g/kg (High margin of safety)
• Symptomatic threshold: ~84 mg/kg Δ9-THC
• Lipophilic auto-entrapment in adipose tissue
• Prolonged enterohepatic recirculation
Compounded Safety Thresholds
Clinical Management Protocol
• High-risk preparation limit: >10 mg/mL
• Rapid concentrate absorption bioavailability
• Acute exposure risks in synthetic cannabis
• SUSMP regulatory compliance verification
• Decontamination: Emesis & Charcoal (<2h)
• Supportive care: Quiet space & thermal care
• IV fluids for hemodynamic support
• Intravenous Lipid Emulsion (ILE 20%)